We are live on
!
Find out more
AC
Amia Capital Portfolio holdings
AUM
$32.1M
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter
Est. Return
-23.58%
1 Year Est. Return
+0.56%
3 Year Est. Return
+30.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$112M
AUM Growth
-$230M
(-67%)
Cap. Flow
-$154M
Cap. Flow
% of AUM
-136.76%
Top 10 Holdings %
Top 10 Hldgs %
85.57%
Holding
48
New
7
Increased
2
Reduced
31
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$655K |
| 2 |
Arvinas
ARVN
|
+$506K |
| 3 |
Scholar Rock
SRRK
|
+$309K |
| 4 |
MTEM
Molecular Templates, Inc.
MTEM
|
+$275K |
| 5 |
CDTX
Cidara Therapeutics
CDTX
|
+$69.1K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
|
+$67.2M |
| 2 |
LSXMA
Liberty Media Corporation Series A Liberty SiriusXM Common Stock
LSXMA
|
+$38.1M |
| 3 |
LSXMK
Liberty Media Corporation Series C Liberty SiriusXM Common Stock
LSXMK
|
+$24.8M |
| 4 |
Petrobras
PBR
|
+$9.43M |
| 5 |
GRFS
Grifois
GRFS
|
+$7.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54% |
| 2 | Communication Services | 4.34% |
| 3 | Materials | 3.32% |
| 4 | Energy | 0.05% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GRFS
1
Grifois
GRFS
$5.35B
| $36.3M | 32.3% |
1,803,856
-354,050
| -16% | -$7.93M |
|
|
LSXMA
2
DELISTED
Liberty Media Corporation Series A Liberty SiriusXM Common Stock
LSXMA
| $21.3M | 18.93% |
929,782
-1,205,825
| -56% | -$38.1M |
|
|
LSXMK
3
DELISTED
Liberty Media Corporation Series C Liberty SiriusXM Common Stock
LSXMK
| $12.6M | 11.19% |
522,599
-740,582
| -59% | -$24.8M |
|
|
BBL
4
DELISTED
BHP Group Plc American Depositary Shares (Each representing two Ordinary Shares)
BBL
| $6.95M | 6.18% |
228,919
-163,209
| -42% | -$6.43M |
|
5
Liberty Latin America Class A
LILA
$1.48B
| $4.88M | 4.34% |
725,295
-218,916
| -23% | -$2.2M |
|
6
Vale
VALE
$63B
| $3.73M | 3.32% |
450,000
-350,000
| -44% | -$3.81M |
|
7
Ionis Pharmaceuticals
IONS
$8.83B
| $3.29M | 2.93% |
69,678
-22,834
| -25% | -$1.27M |
|
8
Vertex Pharmaceuticals
VRTX
$121B
| $2.57M | 2.29% |
10,809
-3,588
| -25% | -$823K |
|
9
Neurocrine Biosciences
NBIX
$17.6B
| $2.44M | 2.17% |
28,139
-6,633
| -19% | -$649K |
|
10
Incyte
INCY
$23.3B
| $2.17M | 1.93% |
29,635
-10,382
| -26% | -$784K |
|
11
Alnylam Pharmaceuticals
ALNY
$35.5B
| $1.52M | 1.35% |
13,946
-3,957
| -22% | -$457K |
|
12
Moderna
MRNA
$23.2B
| $1.26M | 1.12% |
41,993
-11,083
| -21% | -$255K |
|
13
Halozyme
HALO
$9.24B
| $1.25M | 1.11% |
69,409
-20,164
| -23% | -$383K |
|
14
iShares Biotechnology ETF
IBB
$9.31B
| $1.21M | 1.07% |
11,207
-33,232
| -75% | -$3.83M |
|
15
Agios Pharmaceuticals
AGIO
$2.14B
| $1.21M | 1.07% |
33,958
-5,312
| -14% | -$245K |
|
16
argenx
ARGX
$53.7B
| $1.08M | 0.96% |
8,235
-1,785
| -18% | -$261K |
|
|
ALXN
17
DELISTED
Alexion Pharmaceuticals
ALXN
| $1.03M | 0.91% |
11,452
-3,394
| -23% | -$333K |
|
|
ESPR
18
DELISTED
Esperion Therapeutics
ESPR
| $1.02M | 0.91% |
32,492
-8,071
| -20% | -$426K |
|
|
RDUS
19
DELISTED
Radius Health, Inc.
RDUS
| $780K | 0.69% |
59,983
-15,616
| -21% | -$278K |
|
|
MYOK
20
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $517K | 0.46% |
11,019
-2,597
| -19% | -$166K |
|
|
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $463K | 0.41% |
+30,144
| New | +$655K |
|
|
22
Arvinas
ARVN
$534M
| $436K | 0.39% |
+10,815
| New | +$506K |
|
23
Exelixis
EXEL
$13.9B
| $426K | 0.38% |
24,712
-5,384
| -18% | -$98.5K |
|
24
Nektar Therapeutics
NKTR
$2.33B
| $408K | 0.36% |
1,523
-279
| -15% | -$86.3K |
|
|
ICPT
25
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $382K | 0.34% |
6,067
-1,611
| -21% | -$145K |
|
Similar funds
QI
SAM
FCMI
AG
NLG
BEVI
BGDR
TAAM
Amia Capital's Q1 2020 Portfolio in Review
As of Q1 2020, Amia Capital held 48 positions worth $112M, down 67% from $343M the previous quarter. Its ten largest holdings account for 86% of the portfolio.
Amia Capital withdrew a net $154M in Q1 2020, closing 8 positions and reducing 31 holdings. Its most notable exit was iShares JPMorgan USD Emerging Markets Bond ETF, an estimated $67.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 26% a quarter earlier, followed by Communication Services and Materials.
Against the trend, Amia Capital opened a new position in Intra-Cellular Therapies Inc. worth $463K.
- Amia Capital's largest Q1 2020 buy was Intra-Cellular Therapies Inc.: 30,144 shares worth $463K.
- Amia Capital added most to Voyager Therapeutics in Q1 2020, an estimated $42.2K increase.
- Amia Capital's biggest Q1 2020 reduction was Liberty Media Corporation Series A Liberty SiriusXM Common Stock, cutting an estimated $38.1M.
- Amia Capital fully exited iShares JPMorgan USD Emerging Markets Bond ETF in Q1 2020, selling an estimated $67.2M.
- Amia Capital's ten largest holdings make up 86% of its $112M portfolio in Q1 2020.
- Amia Capital opened 7 new positions and closed 8 in Q1 2020.
- Amia Capital's portfolio value fell 67% quarter-over-quarter to $112M.
Based on Amia Capital's 13F filing for Q1 2020, filed 15 May 2020.